What is clear is that to be overly didactic based on an abstract alone falls far short of the dictum, 'Know the literature and never get caught without a reference.
Couldn't agree more, wish I had the time and resources to read everything. Waste enough time doing this as it is.
Here is another interesting abstract on "death switches"
ncbi.nlm.nih.gov
(seems like a nice example of someone outside Ariad taking advantage of the availability of ARGENT reagents)
It is also quite apparent that those "whose knowledge (is) incomplete" do constitute the large majority of the readers of this and other boards (present company excluded, of course). It is easy to forget that although one posts to "a" person, what we write reaches a number of people.
In the same spirit, it seems that an interesting exercise may be to figure out what would it take to implement in the clinic, say, the kind of work described in Science a year ago by Ariad, Wilson et al. This may give the investor an idea of how soon, and perhaps at what cost, Ariad or a prospective partner will be able to realize at least this aspect of the clinical potential of ARGENT. For extra credit, one can try to figure out what will be needed to add the "fail-safe" feature to the above (not sure it would make sense if simple withdrawal of the dimerizing drug would effectively shutdown expression, if the system is not "leaky").
PB |
